EP1357898A2 - Forme posologique orale a liberation regulee amelioree - Google Patents

Forme posologique orale a liberation regulee amelioree

Info

Publication number
EP1357898A2
EP1357898A2 EP02723104A EP02723104A EP1357898A2 EP 1357898 A2 EP1357898 A2 EP 1357898A2 EP 02723104 A EP02723104 A EP 02723104A EP 02723104 A EP02723104 A EP 02723104A EP 1357898 A2 EP1357898 A2 EP 1357898A2
Authority
EP
European Patent Office
Prior art keywords
dosage form
bupropion
composition
polymer
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02723104A
Other languages
German (de)
English (en)
Other versions
EP1357898A4 (fr
Inventor
Boyong Li
Chih-Ming Chen
Xiu Xiu Cheng
Avinash Nangia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Publication of EP1357898A2 publication Critical patent/EP1357898A2/fr
Publication of EP1357898A4 publication Critical patent/EP1357898A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Definitions

  • the present invention relates to oral controlled release dosage formulations containing bupropion hydrochloride.
  • bupropion hydrochloride The compound designated bupropion hydrochloride is described in United States Patent Nos. 3,819,706 and 3,885,046. It is marketed as an anti- depressant and an aid to smoking cessation. Bupropion is an arninoketone-derivative chemically unrelated to other currently available antidepressants (e.g., selective serotonin-reuptake inhibitors, tricyclics, tetracyclics).
  • antidepressants e.g., selective serotonin-reuptake inhibitors, tricyclics, tetracyclics.
  • Bupropion does not inhibit monoamine oxidase and is a weak blocker of serotonin and norepinephrine uptake.
  • the drug is useful in the treatment of depressive affective disorders (e.g., major depression) at dosages of 75 to 600 mg daily.
  • Bupropion may be preferable to other agents because of its minimal anticholinergic, cardiovascular, and antihistaminic effects or in those patients who have experienced weight gain or sexual dysfunction with another antidepressant.
  • Bupropion, as extended-release tablets is used in the cessation of smoking at dosages of 100-300 mg daily. Withdrawal symptoms and cigarette craving are reduced with bupropion.
  • Other uses include patients with bipolar depression, attention-deficit hyperactivity in both adult and pediatric patients, and panic symptoms superimposed on depression.
  • Immediate release bupropion tablets provide more than 75% of bupropion release into the dissolution media in 45 minutes.
  • the risk of seizures appears to be strongly associated, in part, with the use of instant release tablets.
  • One common technique involves surrounding an osmotically active drug core with a semipermeable membrane.
  • the drug is released from the core over time by allowing a fluid such as gastric or intestinal fluid to permeate the coating membrane and dissolve the drug so the dissolved drug can permeate through the membrane.
  • a hydrogel is employed to push the active ingredient through the passageway of the membrane.
  • Another common technique for preparing controlled-release pharmaceutical formulations is to encapsulate a plurality of beads, pellets or tablets that are coated with varying levels of diffusion barriers.
  • the barriers can be of the same or different chemical composition. Release of the pharmaceutical may occur by leaching, erosion, rupture, diffusion or similar actions depending on the nature and thickness of the coating material. These products require multi-layered coating, sometimes as much as 30 to 90 coats.
  • Film coating techniques are characterized by the deposition of a uniform film onto the surface of a substrate. Because of the capability of depositing a variety of coating materials onto solid cores, this process has been used to make controlled release dosage forms starting from different formulations, such as tablets, granules, pellets and capsules. Cores are usually prepared using one of the following processes: compaction, surface layering, or agglomeration.
  • Bupropion hydrochloride is highly soluble in water with a high permeability characterized by rapid and almost complete absorption. Peak plasma concentrations occur within 2 hours for bupropion and 3 hours for bupropion sustained-release. Its biphasic pharmacokinetics is characterized by a two- compartment model; the distributive phase has a mean half-life of 3 to 4 hours with a biphasic decline and a terminal T Vz of about 14 hours following single doses. A major drawback is extensive first-pass metabolism It appears that only a small portion of any oral dosage reaches the systemic circulation intact. Immediate-release tablets are dosed three times a day, preferably with 6 or more hours separating the doses.
  • each divided dose should not exceed 150 mg each. This necessitates administration of the tablets 4 times daily with at least 4 hours between successive doses.
  • Commercially available sustained-release products are available in film-coated tablets marketed by Glaxo Wellcome under the tradenames Wellbutrin® SR and Zyban®. These are dosed twice daily. For those patients requiring above 300 mg daily, the regimen remains twice daily dosing. No currently available product provides a sustained release profile suitable for once daily dosing.
  • Patient compliance is especially problematic in depressed patients. There is a need for improved patient compliance.
  • One of the means employed clinically to improve patient adherence to therapy is simplification of the dosing regimen.
  • simplification of the dosing regimen is simplification of the dosing regimen.
  • Sustained release tablet forms of bupropion are described in United States Patent No. 5,427,798, comprising a sustained release tablet which provides peak bupropion blood levels at approximately 2-3 hours, thereby requiring twice daily dosing. Controlled release is achieved by combining bupropion particles with microcrystalline cellulose and hydrogel-forming hydroxypropyl methylcellulose.
  • Another sustained release bupropion tablet or caplet formulation disclosed in United States 4,687,660 comprises a difficult manufacturing process and limited shelf life.
  • United States Patent No. 5,358,970 discloses a formulation of bupropion hydrochloride that contains an acid stabilizer.
  • United States Reissue Patent No. 33,994 discloses a tablet formulation of a water insoluble, water-permeable film coating surrounding the drug core and a particulate, water-soluble, pore-forming material dispersed within the film coating; this osmotic gradient and channel forming system is applicable for tablet dosage forms.
  • this osmotic gradient and channel forming system is applicable for tablet dosage forms.
  • at least twice daily dosing is necessitated by the release profile of 25-70% of bupropion within 4 hours, and 40-90%) within 6 hours.
  • Wellbutrin® SR is a commercially available twice a day dosage form of bupropion which contains carnauba wax, cysteine hydrochloride, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol and titanium dioxide.
  • Immediate release tablets must be stored at a temperature above 15- 25°C and protected from light and moisture. Extended-release tablets should be stored in tight, light-resistant containers at a temperature of 20-25°C.
  • C max maximum plasma concentration
  • Such a delayed delivery dosage form has a practical application, and it represents a valuable contribution to the medical arts.
  • the present invention provides such a composition, and offers an efficient and cost effective method of preparation.
  • Another object of the present invention is to provide a capsule dosage form comprising means for delaying delivery of the drug in gastric fluids for 6 hours up to 12 hours, usually 4 hours to 8 hours. It is also an object of this invention to provide a controlled and extended release bupropion capsule formulation that is easy to manufacture and can be used to prepare a range of dosing levels suitable for once daily administration.
  • Another object of this invention is to provide simplified once daily dosing regimen with the potential to prevent or reduce the incidence of seizures caused by bupropion.
  • the present invention also relates to anew sustained release bupropion pharmaceutical composition producing novel blood plasma levels after ingestion over 24 hours that is not disclosed in, nor rendered obvious by, the prior art.
  • Other objects, features and advantages of the invention are not taught in the prior art but will be more apparent to those versed in the art from the following specification, taken in conjunction with the drawings.
  • the present invention meets the unfulfilled needs of the pharmaceutical industry.
  • the current invention involves a new pelletization process, typified by the application of a bupropion/cellulose ether suspension to inert spheres and two unique formulations of sustained release coatings that are applied to separate active pellets.
  • the formulation functions by membrane-controlled extended-release in a pH dependent manner.
  • the bupropion release rate has been improved by the introduction of two types of film coated active pellets that release the drug at different pH resulting in novel dissolution profiles.
  • Inert spheres are initially coated with bupropion and hydroxypropyl methylcellulose.
  • the active pellets containing bupropion comprise 70-75 weight % of the dosage form.
  • An enteric coating, applied to about one third of the active drug pellets, is comprised of a film insoluble at low pH, such as hydroxypropyl methylcellulose phthalate.
  • the second coating applied to the other two thirds of . active drug pellets is comprised of a combination of a hydrophobic coating agent and methyl acrylic acid copolymer.
  • the two pellet types are then combined in a capsule.
  • the weight ratio of the first pellet to the second pellet will be from about 90:10 to about 10:90, although a weight ratio of from about 30:70 to about 70:30 is preferred. Especially preferred is a weight ratio of about 33.3:66.7.
  • This formulation can provide 24-hour efficacy with once daily dosing, with less than 50% of the drug released at 10 hours. Therapeutic plasma levels are maintained from 12 to 24 hours. The usual dosage range is 75-450 mg.
  • an uncoated bupropion component is also employed.
  • bupropion powder or granules, or the uncoated active pellets may be used directly (first component).
  • the bupropion release rate is further modified and improved by the introduction of uncoated bupropion and the two types of film coated active pellets that release the drug at different pH resulting in further novel dissolution profiles.
  • the enteric coating (hydroxypropyl methylcellulose phthalate) is applied to from about 10 to about 90 weight percent of the active drug pellets (second component).
  • the second coating (hydrophobic and methyl acrylic acid copolymer) is applied to from about 90 to about 10 weight percent of active drug pellets (third component).
  • the three components are then combined in a capsule.
  • the weight ratio of the first component to the second component may vary from about 1:50 to about 50:1
  • the weight ratio of the first component to the third component may vary from about 1:50 to about 50:1
  • the weight ratio of the second component to the third component may vary from about 10:90 to about 90:10, although a weight ratio of from about 30:70 to about 70:30 is preferred.
  • FIG.l is a graph depicting the dissolution profile in a pH 7.5 buffer of the formulations as described in Examples 1 and 3 versus the dissolution of the commercially available sustained release form of bupropion (Wellbutrin® SR).
  • FIG 2. is a graph depicting the dissolution profile in simulated gastric fluid (pH 1.5) of the formulations as described in Examples 1 and 3 versus the dissolution of the commercially available sustained release form of bupropion (Wellbutrin® SR).
  • FIG. 3 is a graph depicting the mean plasma concentration-time profiles of bupropion in seven healthy subjects (smokers) following a single oral dose of the formulation in Example 2 versus 150 mg of the commercially available sustained release product (Zyban®).
  • FIG. 4 is a graph depicting the mean plasma concentration-time profiles of bupropion in seven healthy subjects (smokers) following a single oral dose of the formulation in Example 4 versus 150 mg of the commercially available sustained release product (Zyban®). DETAILED DESCRIPTION OF THE PRESENT INVENTION
  • the present invention in a first embodiment provides a two component controlled release bupropion formulation for oral administration, the formulation comprising:
  • a first pellet comprising: (i) a core comprising:
  • a second pellet comprising: (i) a core comprising:
  • the immediate release bupropion component may comprise any form of immediate release bupropion. This may take the form of uncoated bupropion granules or powders, may comprise bupropion active pellets (as described hereinbelow), may include bupropion granules or active pellets coated with a highly soluble immediate release coating, such as an Opadry® type coating, as are known to those skilled in the art (see generally, United States Patent No. 5,098,715), or a combination of any of the foregoing.
  • a highly soluble immediate release coating such as an Opadry® type coating
  • the active pellets of bupropion hydrochloride useful in the practice of the present invention are preferably based on active pellets having a core forming inert component that may comprise any type of commonly known pellet starting material, which may be water insoluble, such as, but not limited to, cellulose spheres or silicon dioxide, or may be water soluble, such as, but not limited to, starch or sugar spheres having a diameter ranging from about 15 to about 50 mesh, preferably ranging from about 30 to about 35 mesh.
  • the preferred pellet starting material is sugar spheres, NF, containing not less than about 62.5 percent and not more than about 91.5 percent of sucrose.
  • the spheres should have consistent bulk density, low friability, and low dust generation properties.
  • the inert core is preferably coated with an aminoketone antidepressant agent or a pharmaceutically acceptable salt or stereoisomer thereof Most preferably, the core drug is bupropion hydrochloride.
  • the core forming inert component is coated with a formulation that comprises bupropion hydrochloride and a binding agent.
  • the binding agent should be water soluble, and should possess high adhesivity and an appropriate viscosity, to guarantee good adhesion between the sugar cores and bupropion particles, resulting in a high concentration of drug in the pellets.
  • the binding agents employed can be any type of binding agent commonly known in the art such as polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, low molecular weight hydroxypropyl methylcellulose (HPMC), polymethacrylate or ethyl cellulose.
  • the binding agent is a water-soluble polymer such as hydroxypropyl methylcellulose having a viscosity in the range of 2- 12 cps at 20°C, preferably 4-6 cps, such as the material sold as Methocel® E5.
  • a preferred composition of the binder for bupropion is about 2-10% w/w, and most preferably 3-5%.
  • the active pellets of the present invention will preferably comprise the following ingredients:
  • Bupropion HC1 40-80% 60-70%
  • the active pellets for use in the practice of the present invention that comprise the bupropion are typically prepared by forming a suspension of the binder and the drug and then layering the suspension onto the starting pellet using any of the layering techniques known in the industry, such as fluidized bed coating, rotor granulation or pan coating.
  • the suspension medium may comprise any low viscosity solvent, such as isopropyl alcohol, ethanol, water, mixtures thereof and the like. A sufficient amount of coating is applied to provide the desired level of bupropion.
  • These active pellets may be used directly as the first component of the three component formulations of the present invention.
  • the active pellets are also useful in preparing the other two components of the present invention (both the two component and three component formulations).
  • the active pellets intended for such use are divided into two groups, each group receiving a film coating that releases the drug at a different pH.
  • One group of pellets is coated to release drug at a pH corresponding to about 4.8 and lower, which is likely to occur in the upper gastrointestinal (GI) tract; the other group of pellets is film coated to release drug at a pH of 7 and above, which is likely to occur in the lower GI tract.
  • GI gastrointestinal
  • one group of pellets (enteric component) is coated with a film comprising a pH dependent coating polymer, a plasticizer and a lubricant.
  • This group of pellets preferably comprises from about 10 to about 90 weight percent of the total pellets, preferably from about 30 to about 70 weight percent, and most preferably from about 33 to about 60 weight percent.
  • the pH dependent coating polymer may be selected from those enteric coatings known to those skilled in the art.
  • the pH dependent coating is selected from the group consisting of shellac, methacrylic acid copolymers (such as, but not limited to Eudragit® E100 (a cationic copolymer of dimethyl aminoethyl methacrylate and neutral methacrylic acid esters)), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, polyvinyl acetate phthalate or mixtures thereof. Hydroxypropyl methylcellulose phthalate (HPMCP) is preferred.
  • the preferred concentration is 2-10% w/w of the total dosage form, and most preferably 3- 5%.
  • the coating preferably also contains plasticizers.
  • Plasticizers that may be used in the practice of the present invention include any of those known to those skilled in the art, including, but not limited to, acetyltributyl citrate, triacetin, acetylated monoglyceride, rape oil, olive oil, sesame oil, acetyltriethyl citrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumerate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylphthalate, dibutylsebacate, triethyl citrate, tributyl citrate, glyceroltributyrate, polyethylene glycol, propylene glycol and mixtures thereof
  • the preferred plasticizer is acetyltributyl citrate in an amount ranging from about 1 to about 15 percent based on the total weight of the final
  • the coating further preferably includes a lubricant such as, but not limited to, those selected from the group consisting of glyceryl monostearate; Myvaplex 600P, calcium stearate or stearic acid.
  • a lubricant such as, but not limited to, those selected from the group consisting of glyceryl monostearate; Myvaplex 600P, calcium stearate or stearic acid.
  • the preferred lubricant is glyceryl monostearate in an amount ranging from about 1 to about 15 percent, and most preferably 1-2.5% based on the total weight of the coating.
  • a preferred enteric coating for use in the present invention therefore comprises the following ingredients: INGREDIENT PREFERRED MOST
  • Additional active drug pellets for forming the second coated component of the present invention preferably from about 90 to about 10 weight percent of the total pellets, more preferably from about 70 to about 30 weight percent, and most preferably from about 67 to about 40 weight percent, are coated with a coating that comprises a polymer such as a methacrylic copolymer, water insoluble polymer, a plasticizer and an anti-sticking agent.
  • a coating that comprises a polymer such as a methacrylic copolymer, water insoluble polymer, a plasticizer and an anti-sticking agent.
  • the methacrylic acid copolymer is selected from the known group of methacrylic acid copolymers, preferably Eudragit® S (methacrylic acid copolymer Type B), and most preferably Eudragit® SI 00.
  • the preferred concentration is 1-15% of the total weight of the dosage form, preferably 4-7%.
  • the water insoluble polymer in the preferred embodiments of the present invention is formed from a cellulose ester, or a cellulose ester-ether.
  • Representative materials include a member selected from the group consisting of ethyl cellulose, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate butyrate, mono-, di- and tri-cellulose arylates, and the like.
  • Preferred is ethyl cellulose in a concentration ranging from about 1 to about 20%, preferably from about 2 to about 13%.
  • the preferred plasticizer additive for the second coating may be selected from any of those mentioned above. Acetyltributyl citrate is preferred.
  • the anti-sticking agents can be chosen from any of the known agents, such as, but not limited to, those selected from the group consisting of an alkaline earth metal stearate, such as magnesium stearate or calcium stearate, or talc.
  • the anti- sticking agents can be used alone or in combination in effective amounts.
  • the preferred anti-sticking agent is talc.
  • the coating for the active pellet for this (second coated) component of the present invention is applied to the active pellets by forming a solution of the respective coating components in a solvent or a mixture of solvents, such as, but not limited to, acetone and isopropyl alcohol, and employing any of the application techniques known to those skilled in the art, such as fluidized bed coating, rotor granulation or pan coating.
  • the components, either the two coated or the two coated and the immediate release, of the present invention are blended together in the desired ratio and placed in gelatin capsule to obtain a finished product.
  • novel dissolution profiles and plasma profiles may be obtained in accordance with the present invention.
  • the dosage formulation may be made into tablets by first adding from 25 to 40 weight percent of a solid pharmaceutically acceptable tablet excipient that will form a compressible mixture without crushing the pellets, and then tabletting the mixture in a suitable tablet press.
  • a batch of controlled release bupropion was manufacture using all materials that comply with the current USP/NF compendia specifications.
  • a controlled release 150 mg oral bupropion dosage form is prepared by forming active core pellets having the following composition:
  • Active pellets of bupropion are formed by dissolving 2.8 kg of bupropion HCl and 0.140 kg of hydroxypropyl methylcellulose (Methocel® E5) in a mixture of water and isopropyl alcohol. The active drug solution is then sprayed onto 1.06 kg of sugar spheres 30/35 in a fluidized bed processor with a Wurster insert. The active core pellets are then dried in a fluidized bed processor until the loss on drying is below 1%. The bupropion pellets are then passed through a 16 mesh screen and a 30 mesh screen and pellets are collected that are smaller than 16 mesh and larger than 30 mesh.
  • Bupropion active pellets 75.0%
  • LOD LOD
  • 2% (w/w) talk for 10 minutes in a N-blender The pellets are then passed through a 14 mesh screen and a 24 mesh screen and pellets that are smaller than 14 mesh and larger than 24 mesh are collected.
  • a coating is prepared where the ratio of the methacrylic acid copolymer to ethylcellulose is about 9:1.
  • the coating is made as follows: 0.378 kg of methacrylic acid copolymer (Eudragit® S 100), 0.42 kg of ethylcellulose (Ethocel® 10 cps), and 0.060 kg of acetyltributyl citrate are dissolved in a mixture of 0.690 kg acetone and 6.210 kg isopropyl alcohol. 0.120 kg of talc is then dispersed into the solution above. The suspension is then sprayed onto 2.40 kg of the active bupropion core pellets in a fluidized bed processor with a Wuster insert.
  • the bupropion pellets are dried in a fluidized bed processor until the LOD is less than 1%.
  • the pellets are mixed with 2% (w/w) talc for 10 minutes in a N-blender and passed through a 14 mesh screen and 24 mesh screen. Pellets smaller than 14 mesh and larger than 24 mesh are collected.
  • the enteric coated pellets and the SR pellets are mixed after loading each group into dosators.
  • the strength of the final product is 150 mg of bupropion with 50 mg of active drug in the first group of pellets and 100 mg of active in the second group.
  • the pellets are then encapsulated into size "1" light turquoise blue/light turquoise blue capsules.
  • the total weight of the formulation (capsule + pellets) is 350 mg.
  • the resulting bupropion capsules of Example 1 were then tested according to the USP XXIII dissolution test (type 2, basket) at 50 rpm, at 37°C in pH 7.5 buffer and found to have the following release profile:
  • the release profile of the controlled release product shown in this Example is shown in FIG. 1 by the line filled with circles.
  • Example 1 The bupropion capsules of Example 1 were then tested according to the USP XXIII dissolution test (type 2, basket), at 50 rpm, at 37°C in SGF (pH 1.5) to determine the percentage of drug dissolved versus time.
  • the release profile of the controlled release product shown in this Example 1 is shown in FIG. 2 by the line with the filled circles.
  • the bupropion capsules of Example 1 were then evaluated in seven patients using standard techniques known in the art. Bupropion was first detected in the plasma at about 2 hours after administration, and showed sustained release over 24 hours.
  • Two panels of seven patients were randomly assigned to receive either the bupropion formulation described herein or ZYBAN® in an open, randomized single dose study. Blood samples were collected over a 72-hour period and analyzed for bupropion concentrations with a LC/MS/MS method.
  • C max is the maximum blood level concentration of bupropion
  • T max is the time at which the maximum blood level concentration occurs
  • T ⁇ ag is the sampling point preceding the one at which concentrations first become quantifiable.
  • AUC is the "area under the curve" of time versus blood concentration.
  • EXAMPLE 2 The pellets from Example 1 are taken as the second and third components. These pellets are loaded into the dosator along with active pellets and are filled into capsules in a ratio of 10:30:60 while maintaining the dosage at 150 mg.
  • the blood profiles from this example will show a C max that is the same as shown in Table 3, but will show a slightly increase AUC, thereby rendering the G-Mean ratio at about 1.00.
  • the amount of active pellets may be adjusted as is known in the art without undue experimentation based on the teachings of the present disclosure in order to substantially provide a G-Mean for AUC of approximately 1.00.
  • EXAMPLE 3 The procedure of the Example 1 is followed for the first group of pellets.
  • the bupropion cores are prepared by forming a suspension of bupropion and hydroxypropyl methylcellulose in a mixture of water and isopropyl alcohol, which suspension is spray coated onto inert spheres.
  • the HPMCP enteric coating is then applied to about one third of the active drug pellets.
  • a second group of about two-thirds of the pellets is coated with a coating prepared where the ratio of methacrylic acid copolymer to ethylcellulose is about 1:1.
  • the pellets have the following composition:
  • the coating is made as follows: 0.105 kg of methacrylic acid copolymer (Eudragit® S100), 0.105 kg of ethylcellulose (Ethocel® 10 cps), and 0.030 kg of acetyltributyl citrate are dissolved in a mixture of 0.345 kg acetone and 3.105 kg isopropyl alcohol. 0.060 kg of talc is then dispersed into the solution above. The suspension formed is then sprayed onto 1.20 kg of the active bupropion core pellets in a fluidized bed processor with a Wurster insert. The coated bupropion pellets are then dried in a fluidized bed processor until the LOD is less than 1%. The pellets are mixed with 2% (w/w) talc for 10 minutes in a N-blender and passed through a 14 mesh screen and a 24 mesh screen. Pellets smaller than 14 mesh and larger than 24 mesh are collected.
  • the pellets have the following coating composition: Ingredient mg/Capsule % Total Wt.
  • the first group of pellets and the 1:1 above pellets are mixed after loading each group into dosators.
  • the strength of the final product is 150 mg of bupropion with 50 mg of active drug in the first group of pellets and 100 mg of active drug in the second group.
  • the pellets are then encapsulated into size "1" buff opaque/light blue opaque capsules.
  • the total weight of the formulation (capsule + pellets) is 352 mg.
  • the resulting bupropion capsules were then tested according to the USP XXIII dissolution test (type 2, basket), at 50 rpm, at 37°C, in pH 7.5 buffer and found to have the following release profile:
  • the resulting bupropion capsules were then tested according to USP XXIII dissolution test (type 2, basket), at 50 rpm, at 37°C, in SGF (pH 1.5) and found to have the following release profile:
  • the bupropion capsules of Example 3 were then analyzed in a seven patient test using techniques known in the art. Bupropion was first detected in the plasma about 1.4 hours after administration and showed a sustained release over 24 hours.
  • Example 1 The testing procedure is as described in Example 1. The results provided are given in Table 4 and FIG. 4 and show that the mean plasma-time profile of the bupropion formulation differs from that of Zyban®. Bupropion had a delayed absorption; the relative bioavailability of bupropion to Zyban® was 48% and 59% in terms of C max and AUC values, respectively. The terminal elimination half-lives were similar.
  • Example 3 The pellets from Example 3 are taken as the second and third components. These pellets are loaded into the dosator along with active pellets and are filled into capsules in a ratio of 10:30:60 while maintaining the dosage at 150 mg bupropion.
  • the blood profiles from this example will show a C max the same as in Table 3, but will show a slightly increased AUC, thereby rendering the G-mean ratio at about 1.00.
  • the amount of active pellets may be adjusted as is known in the art without undue experimentation based on the teachings of the present disclosure in order to substantially provide a G-Mean for AUC of approximately 1.00.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une formulation d'hydrochlorure de bupropion à prise quotidienne.
EP02723104A 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree Withdrawn EP1357898A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26745701P 2001-02-08 2001-02-08
US26745601P 2001-02-08 2001-02-08
US267457P 2001-02-08
US267456P 2001-02-08
PCT/US2002/003523 WO2002062299A2 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Publications (2)

Publication Number Publication Date
EP1357898A2 true EP1357898A2 (fr) 2003-11-05
EP1357898A4 EP1357898A4 (fr) 2005-07-13

Family

ID=26952450

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02723104A Withdrawn EP1357898A4 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Country Status (3)

Country Link
EP (1) EP1357898A4 (fr)
CA (3) CA2796884A1 (fr)
WO (1) WO2002062299A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
KR101087464B1 (ko) 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
EP1858493A4 (fr) * 2005-03-14 2010-12-01 Sun Pharmaceutical Ind Ltd Systeme d'administration de medicament par voie orale
WO2008064192A2 (fr) 2006-11-21 2008-05-29 Mcneil-Ppc, Inc. Suspensions analgésiques à libération modifiée
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
JP2012528799A (ja) * 2009-06-02 2012-11-15 ダウ グローバル テクノロジーズ エルエルシー 徐放製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2173096T3 (es) * 1992-08-05 2002-10-16 Faulding F H & Co Ltd Composicion farmaceutica peletizada.
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Also Published As

Publication number Publication date
WO2002062299A2 (fr) 2002-08-15
EP1357898A4 (fr) 2005-07-13
WO2002062299A3 (fr) 2003-04-24
CA2685214A1 (fr) 2002-08-15
CA2685214C (fr) 2013-01-22
CA2433915A1 (fr) 2002-08-15
CA2433915C (fr) 2010-04-20
CA2796884A1 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
US7771750B2 (en) Controlled release oral dosage form
US6589553B2 (en) Controlled release oral dosage form
JP2637981B2 (ja) 吸収制御薬剤組成物
CA2686094A1 (fr) Methode de fabrication d'un element semiconducteur
CA2426883C (fr) Formulations a liberation modifiee par methylphenidate
EP1879556B1 (fr) Systemes de liberation chronocontrolee par impulsions
CA1264296A (fr) Formules a trois niveaux distincts de liberation
AU2002330211B2 (en) Timed, sustained release multi-particulate dosage forms of propranolol
AU757915B2 (en) Controlled release bupropion formulation
JPH0476966B2 (fr)
HUE029680T2 (en) Dispensing systems containing weakly basic active ingredients and organic acids
JP2001507359A (ja) 徐放性シサプリドミニ錠剤製剤
US20030035840A1 (en) Controlled release oral dosage form
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
CA2433915C (fr) Forme posologique orale a liberation regulee amelioree
WO2007117110A2 (fr) Granules à libération prolongée contenant du chlorhydrate de tamsulosine et leurs procédés de préparation
EP1629834A1 (fr) Composition pharmaceutique de tolterodine avec liberation soutenue
WO2013181292A1 (fr) Formulations de nitisinone
AU2002253907A1 (en) Improved controlled release oral dosage form
JP2005510449A (ja) 改良型制御放出経口剤形
AU2013273835B2 (en) Timed, pulsatile release systems
HK1108116B (en) Timed, pulsatile release systems
HK1189799A (en) Timed, pulsatile release systems

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030714

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050601

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/00 B

Ipc: 7A 61K 9/50 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050818